Drug Profile
SRT 2104
Alternative Names: GSK-2245840; SRT-2104Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sirtris
- Developer GlaxoSmithKline
- Class Antihyperglycaemics; Antipsoriatics; Small molecules
- Mechanism of Action SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Chronic obstructive pulmonary disease; Inflammation; Muscular atrophy; Plaque psoriasis; Type 2 diabetes mellitus; Ulcerative colitis
Most Recent Events
- 28 Feb 2013 Sirtris completes a phase Ib trial in Ulcerative colitis in the US (NCT01453491)
- 01 Dec 2012 Sirtris completes a phase I trial (in volunteers) in Plaque psoriasis in USA (NCT01702493)
- 18 Oct 2012 Phase-I clinical trials in Plaque Psoriasis (in volunteers) in USA (PO, tablet)